US equities
|
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Gyre Therapeutics Inc.
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
September 03, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
August 07, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Appoints Three New Members to its Board of Directors
July 16, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
May 12, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 07, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
May 04, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
March 17, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 12, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
January 05, 2026
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
November 07, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
October 15, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
October 14, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 05, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
August 22, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
August 11, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 29, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
May 22, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
June 10, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
May 22, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
May 22, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 09, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
March 31, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
March 27, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 17, 2025
From
Gyre Therapeutics Inc.
Via
GlobeNewswire
Tickers
GYRE
